about
Advances in the management of osteosarcomaTGF-β Signaling in Bone Remodeling and Osteosarcoma ProgressionReview of Osteosarcoma and Current ManagementTargeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma CellsNeoadjuvant chemotherapy combined with limb salvage surgery in patients with limb osteosarcoma of Enneking stage II: a retrospective studyTranscription Factor 21 (TCF21) rs12190287 Polymorphism is Associated with Osteosarcoma Risk and Outcomes in East Chinese PopulationRas-Association Domain Family 1 Isoform A (RASSF1A) Gene Polymorphism rs1989839 is Associated with Risk and Metastatic Potential of Osteosarcoma in Young Chinese Individuals: A Multi-Center, Case-Control Study.Increased zinc accumulation in mineralized osteosarcoma tissue measured by confocal synchrotron radiation micro X-ray fluorescence analysis.Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.Downregulation of BZW2 inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway.CXCL8 promotes the invasion of human osteosarcoma cells by regulation of PI3K/Akt signaling pathway.Suppression of heat shock protein 70 by siRNA enhances the antitumor effects of cisplatin in cultured human osteosarcoma cells.miR-22 promotes apoptosis of osteosarcoma cells via inducing cell cycle arrest.Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.Novel insights and therapeutic interventions for pediatric osteosarcoma.The pharmacogenomics of osteosarcoma.Loss of monocyte chemoattractant protein-1 expression delays mammary tumorigenesis and reduces localized inflammation in the C3(1)/SV40Tag triple negative breast cancer model.Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice.TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p.Assessment of GSK1904529A as a promising anti-osteosarcoma agent.Activation Status of Receptor Tyrosine Kinases as an Early Predictive Marker of Response to Chemotherapy in Osteosarcoma.Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis.Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics.LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1.The synergistic antitumor effect of cinobufagin and cisplatin in human osteosarcoma cell line in vitro and in vivo.Antitumor effects of pristimerin on human osteosarcoma cells in vitro and in vivo.Long non-coding RNA ZFAS1 sponges miR-486 to promote osteosarcoma cells progression and metastasis in vitro and vivo.Understanding the Osteosarcoma Pathobiology: A Comparative Oncology Approach.Genetic Polymorphisms of Insulin-Like Growth Factor 1 Are Associated with Osteosarcoma Risk and Prognosis.SphK2 over-expression promotes osteosarcoma cell growth.Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma.Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: A brief review.DownRegulated SOX4 Expression Suppresses Cell Proliferation, Migration, and Induces Apoptosis in Osteosarcoma In Vitro and In Vivo.LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2.MSP-4, an Antimicrobial Peptide, Induces Apoptosis via Activation of Extrinsic Fas/FasL- and Intrinsic Mitochondria-Mediated Pathways in One Osteosarcoma Cell Line.Experimental study of inhibitory effects of diallyl trisulfide on the growth of human osteosarcoma Saos-2 cells by downregulating expression of glucose-regulated protein 78.The extremity localized classic osteosarcomas have better survival than the axial non-classics.
P2860
Q28067644-827379A5-CBFD-43CC-A59F-B771FA5F4B9CQ28076815-6029051C-A7B6-4493-A281-6E94AE193349Q28077590-38963EA2-8BD5-4248-A63E-150636E8A17BQ28554501-1CEB0765-7D5A-4285-BFCC-9F7D47174C12Q33758207-7CA4B07D-5C18-49FF-A03B-D591CC64D7CCQ33888122-22B67163-B827-4DDB-AD4C-6E63071F8F2AQ37462883-74F4E0A4-4A49-4A15-A490-9406C6B71131Q37633403-8E98D668-B4B5-4733-A4C5-202CB102669CQ37641721-98CBADFF-FFFE-47BF-B426-8DED037BD81FQ37705973-484F4377-B954-487B-A60D-28BA76244632Q38632877-44BA50AE-B43A-452E-85F3-73E50E640434Q38696540-DEB3B4A1-3F39-45E5-8163-F1ADB178E684Q38705123-1D554B1A-D91E-4C89-B276-8EB594CE60A0Q38705618-EB62D4CD-8D7A-4362-887E-0FAF4E940452Q38791215-C6BD6B51-7A87-42DB-A5CF-63A0D828785EQ38805212-A6E0E30B-2952-459A-8581-722727242FE4Q38809116-CCC5143A-AEEB-4309-8EA1-23475A3FDB4DQ38819276-CD283687-4E01-4FD7-9BB0-786B88E66FF8Q38848413-81F0B6B1-16C5-439C-95BB-CF81273357C0Q39027509-8464F01F-5C9B-443A-B15B-5C00874B0847Q40398428-517BF2C3-A63D-4FFD-8011-EAA8369649EBQ41388665-B157D400-8EAC-4BBF-81A2-9AA69468709CQ41472644-9B9BE05F-8C6E-4B3E-8A89-CDE924AAEC3BQ41624093-EAACB52F-732F-4777-BD9F-3A9D23BCBD92Q41883809-F4A36F86-C4CD-4BCF-B4F7-A52C85393AD9Q42634367-3FC6FB7C-18BA-4A60-879D-50E0DABA597AQ42654010-7FE4A60A-B325-4350-ADD0-4B6C876A4BFBQ46514406-C28472B4-212D-4990-8DEB-0F6D0D1AD175Q47096522-AC749AF8-26B1-493C-A240-572758D38D0FQ47128979-11854FB1-8F7F-40AB-8787-FF83FE36FB92Q47132356-94760ADB-6454-4F73-883A-F1B3E2164EB7Q47138734-E969B727-9EB6-459C-A0D6-9A18837FB6CCQ47140549-DBE5F30C-F3B4-4ED0-8D1C-DF3BAFE56295Q47320107-E2DD0F03-4C52-42BD-B17F-16411D376C4BQ47567325-A6CA3E1B-D063-4CBE-A2F9-4EF149099CCFQ47642773-9E003F62-C36A-405A-905E-EAFFF6FE68DFQ48270542-7F73CD6D-AB48-4B50-9987-D733085C0F6DQ48308567-8C98F28C-C093-446B-A4D9-EA96105D0B74Q49415195-5D6B27A8-655C-4D2E-9247-196461FAB028Q50315172-F4D93A46-BE99-42AD-B3B3-FE67D1348E8F
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
An update on chemotherapy for osteosarcoma.
@en
type
label
An update on chemotherapy for osteosarcoma.
@en
prefLabel
An update on chemotherapy for osteosarcoma.
@en
P2860
P1476
An update on chemotherapy for osteosarcoma.
@en
P2093
Stefano Ferrari
P2860
P304
P356
10.1517/14656566.2015.1102226
P407
P577
2015-10-29T00:00:00Z